Skip to main content

Table 2 Cost (USD at 2018 levels) per QALY by drug price and PrEP Efficacy

From: Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel

PrEP Efficacy

Price

(a)

(b)

(c)

(d)

(e)

(f)

Decrease

56.3%

70.0%

78.5%

86.0%

90.0%

97.1%

10%

2,689,603

1,521,835

1,174,811

967,744

881,831

754,449

25%

2,301,819

1,290,388

989,823

810,477

736,066

625,738

50%

1,655,511

904,643

681,509

548,366

493,124

411,218

70%

1,138,465

596,047

434,858

338,677

298,771

239,603

90%

621,419

287,451

188,206

128,988

104,417

67,988

  1. (a) Current baseline estimate
  2. (b) lower 90%/95% bounds from refs [2, 4, 5]
  3. (c) weighted average from refs [2, 4, 5]
  4. (d) weighted average from refs [4, 5] (baseline)
  5. (e) upper 90%/95% bounds from [2, 4, 5]
  6. (f) ref. [10]
  7. Assumes background decline in HIV for four more years, 80% PrEP take up by high-risk MSM,
  8. 25% PrEP take up by low-risk MSM of whom 75% stop condom use
  9. Based on MOH payment schedule to HMOs for HIV/AIDS patients
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us